Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone.
The purpose of the present paper was to evaluate the relationship between plasma antipsychotics concentration and cognitive task performance. This may provide valuable information for rational dosage titration. Literature on the relationship between plasma risperidone (RIS) concentration and performance on the Continuous Performance Test (CPT) remains scarce. Ten patients (four male, six female) were given RIS for more than 1 year. Steady-state plasma concentrations of the parent drug RIS and its active metabolite, 9-hydroxy-risperidone (9-OH-RIS), were measured using specific liquid chromatography-tandem mass spectrometry assay. Psychopathology, side-effects of extrapyramidal symptoms (EPS) and CPT were also assessed. A negative correlation was found between CPT performance and the plasma RIS, 9-OH-RIS and its active moiety (RIS + 9-OH-RIS) concentrations. Both RIS and 9-OH-RIS have an impact on the CPT performance of schizophrenic patients. Optimal active moiety plasma concentration for best cognitive performance needs further study.
Chen
Po See
PS
Department of Psychiatry, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Yang
Yen Kuang
YK
Su
Sheng-Fang
SF
Liao
Yi-Cheng
YC
Chang
Jung-Wei
JW
Yeh
Tzung Lieh
TL
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D001288:Attention / Q000187:drug effects*; D010054:Brief Psychiatric Rating Scale / Q000706:statistics & numerical data; D004193:Discrimination Learning / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007555:Isoxazoles / Q000493:pharmacokinetics; D008297:Male; D009460:Neurologic Examination / Q000187:drug effects; D009483:Neuropsychological Tests; D000068882:Paliperidone Palmitate; D010364:Pattern Recognition, Visual / Q000187:drug effects; D011594:Psychometrics / Q000706:statistics & numerical data; D011597:Psychomotor Performance / Q000187:drug effects*; D011743:Pyrimidines / Q000493:pharmacokinetics; D011930:Reaction Time / Q000187:drug effects; D018967:Risperidone / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013223:Statistics as Topic; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D007555:Isoxazoles; D011743:Pyrimidines; D018967:Risperidone; D000068882:Paliperidone Palmitate